Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC
Pharmacogenetics plays a key role in personalized cancer treatment. Currently, the clinically available pharmacogenetic markers for metastatic colorectal cancer (mCRC) are in genes related to drug metabolism, such as DPYD for fluoropyrimidines and UGT1A1 for irinotecan. Recently, the impact of host...
Saved in:
Main Authors: | Lucia Scarabel (Author), Alessia Bignucolo (Author), Giuseppe Toffoli (Author), Erika Cecchin (Author), Elena De Mattia (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A National Survey of Medical Oncologist's Opinions and Perceptions for Managing Rash Among mCRC Patients Treated with Panitumumab
by: Kimberly A. Lowe, et al.
Published: (2019) -
TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study
by: Giuseppe Cicero, et al.
Published: (2020) -
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
by: A. Bignucolo, et al.
Published: (2023) -
Review of pharmacogenetics of antiseizure medications: focusing on genetic variants of mechanistic targets
by: Chih-Hsiang Lin, et al.
Published: (2024) -
Association of <i>HLA-G</i> 3'UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer
by: Lucia Scarabel, et al.
Published: (2022)